3.3689
price up icon5.65%   0.1789
 
loading
전일 마감가:
$3.19
열려 있는:
$3.22
하루 거래량:
412.95K
Relative Volume:
0.65
시가총액:
$78.09M
수익:
$317.00K
순이익/손실:
$-53.47M
주가수익비율:
-1.7825
EPS:
-1.89
순현금흐름:
$-49.31M
1주 성능:
+31.64%
1개월 성능:
+105.49%
6개월 성능:
+44.64%
1년 성능:
+135.67%
1일 변동 폭
Value
$3.14
$3.3888
1주일 범위
Value
$2.29
$3.3888
52주 변동 폭
Value
$1.00
$3.83

Immuneering Corp Stock (IMRX) Company Profile

Name
명칭
Immuneering Corp
Name
전화
617-500-8080
Name
주소
245 MAIN STREET, SECOND FLOOR, CAMBRIDGE
Name
직원
54
Name
트위터
Name
다음 수익 날짜
2025-03-19
Name
최신 SEC 제출 서류
Name
IMRX's Discussions on Twitter

IMRX을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
IMRX
Immuneering Corp
3.3663 78.09M 317.00K -53.47M -49.31M -1.89
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
444.19 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
528.23 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
317.08 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
563.28 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
243.24 28.51B 3.81B -644.79M -669.77M -6.24

Immuneering Corp Stock (IMRX) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-12-13 다운그레이드 Morgan Stanley Equal-Weight → Underweight
2024-03-15 다운그레이드 Jefferies Buy → Hold
2024-03-15 재확인 Needham Buy
2024-03-15 다운그레이드 TD Cowen Outperform → Market Perform
2023-12-01 개시 Needham Buy
2023-06-26 재개 Oppenheimer Outperform
2023-04-19 업그레이드 Mizuho Neutral → Buy
2023-04-19 업그레이드 Morgan Stanley Underweight → Equal-Weight
2023-03-30 개시 Mizuho Neutral
2023-02-03 다운그레이드 Morgan Stanley Equal-Weight → Underweight
2022-07-08 개시 Chardan Capital Markets Buy
2022-04-01 개시 Oppenheimer Outperform
2022-01-07 개시 Piper Sandler Overweight
모두보기

Immuneering Corp 주식(IMRX)의 최신 뉴스

pulisher
Jun 18, 2025

Immuneering (IMRX) Target Price Raised by Mizuho Analyst | IMRX Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Chardan Capital Maintains Buy Rating on IMRX with $13 Price Targ - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Metric Deep Dive: Understanding La Rosa Holdings Corp (LRHC) Through its Ratios - DWinneX

Jun 18, 2025
pulisher
Jun 18, 2025

Financial Analysis: TNL Mediagene (TNMG)’s Ratios Unveil Key Insights - DWinneX

Jun 18, 2025
pulisher
Jun 18, 2025

Immuneering (IMRX) Price Target Raised by Mizuho Following Positive Trial Data | IMRX Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Immuneering stock price target raised to $10 at Mizuho on cancer drug data - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

Immuneering's Positive Pancreatic Cancer Trial Data Sparks Bullish Retail Sentiment Even As Profit-Taking Cools Rally - MENAFN.com

Jun 18, 2025
pulisher
Jun 18, 2025

Immuneering’s Positive Pancreatic Cancer Trial Data Sparks Bullish Retail Sentiment Even As Profit-Taking Cools Rally - Asianet Newsable

Jun 18, 2025
pulisher
Jun 17, 2025

Immuneering’s atebimetinibin shows positive survival data in pancreatic cancer - TipRanks

Jun 17, 2025
pulisher
Jun 17, 2025

Immuneering stock rises after positive pancreatic cancer trial data - Investing.com

Jun 17, 2025
pulisher
Jun 17, 2025

Immuneering (IMRX) Reports Promising Phase 2a Trial Results for Pancreatic Cancer Treatment | IMRX Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Pancreatic Cancer Breakthrough: New Drug Shows 94% Survival Rate vs 67% Standard Care in Phase 2a Trial - Stock Titan

Jun 17, 2025
pulisher
Jun 16, 2025

Immuneering Corp holds annual stockholder meeting By Investing.com - Investing.com Canada

Jun 16, 2025
pulisher
Jun 16, 2025

Immuneering Corp holds annual stockholder meeting - Investing.com Australia

Jun 16, 2025
pulisher
Jun 16, 2025

Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025 - The Manila Times

Jun 16, 2025
pulisher
Jun 16, 2025

Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025 - GlobeNewswire Inc.

Jun 16, 2025
pulisher
Jun 13, 2025

Two Sigma Investments LP Purchases 10,126 Shares of Immuneering Co. (NASDAQ:IMRX) - Defense World

Jun 13, 2025
pulisher
Jun 12, 2025

Immuneering Co. (NASDAQ:IMRX) Stock Position Reduced by Millennium Management LLC - Defense World

Jun 12, 2025
pulisher
Jun 06, 2025

Immuneering’s (IMRX) Buy Rating Reaffirmed at Needham & Company LLC - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

Needham Maintains Buy Rating on IMRX with Price Target of $9.00 - GuruFocus

Jun 05, 2025
pulisher
May 29, 2025

Full Immuneering Leadership Team Reveals Latest Pipeline Updates at Prestigious Jefferies Conference - Stock Titan

May 29, 2025
pulisher
May 15, 2025

‘Take the Plunge,’ Says Top Investor About Intel Stock - The Globe and Mail

May 15, 2025
pulisher
May 07, 2025

Oppenheimer Adjusts Price Target for Immuneering (IMRX) to $21.0 - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Immuneering (IMRX) Price Target Adjusted by Oppenheimer Analyst - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Immuneering (IMRX) Price Target Adjusted by Oppenheimer Analyst | IMRX Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

21,432 Shares in Immuneering Co. (NASDAQ:IMRX) Acquired by Marshall Wace LLP - Defense World

May 07, 2025
pulisher
May 07, 2025

Oppenheimer Adjusts Price Target for Immuneering (IMRX) to $21.00 | IMRX Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Immuneering Corp. Reports Promising Q1 2025 Results - TipRanks

May 07, 2025
pulisher
May 06, 2025

Immuneering (IMRX) Stock Rating and Price Target Update | IMRX S - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Immuneering reports Q1 EPS (42c), consensus (58c) - TipRanks

May 06, 2025
pulisher
May 06, 2025

Immuneering (IMRX) Stock Rating and Price Target Update | IMRX Stock News - GuruFocus

May 06, 2025
pulisher
May 05, 2025

Immuneering Corp SEC 10-Q Report - TradingView

May 05, 2025
pulisher
May 05, 2025

Immuneering Reports Breakthrough: Cancer Drug Achieves 13-Month Survival in Late-Stage Pancreatic Cancer Patient - Stock Titan

May 05, 2025
pulisher
May 04, 2025

IMRXImmuneering Corp Latest Stock News & Market Updates - Stock Titan

May 04, 2025
pulisher
May 01, 2025

Charting the Course: Immuneering Corp’s IMRX Stock Prospects - investchronicle.com

May 01, 2025
pulisher
May 01, 2025

What technical indicators reveal about IMRX stock - uspostnews.com

May 01, 2025
pulisher
Apr 30, 2025

Immuneering Co. (NASDAQ:IMRX) Short Interest Update - Defense World

Apr 30, 2025
pulisher
Apr 05, 2025

Immuneering Co. (NASDAQ:IMRX) Shares Bought by HighTower Advisors LLC - Defense World

Apr 05, 2025
pulisher
Apr 02, 2025

Full Executive Team Reveals Next Growth Phase at Major Healthcare Conference - Stock Titan

Apr 02, 2025
pulisher
Mar 28, 2025

Chardan Capital Weighs in on Immuneering FY2025 Earnings - Defense World

Mar 28, 2025
pulisher
Mar 23, 2025

Immuneering’s (IMRX) “Buy” Rating Reaffirmed at Needham & Company LLC - The AM Reporter

Mar 23, 2025
pulisher
Mar 23, 2025

Needham & Company LLC Reaffirms “Buy” Rating for Immuneering (NASDAQ:IMRX) - Defense World

Mar 23, 2025
pulisher
Mar 21, 2025

Immuneering Corp. Reports Promising Cancer Trial Results - TipRanks

Mar 21, 2025
pulisher
Mar 21, 2025

Immuneering Strengthens Leadership: New CMO Joins with $212K Stock Option Grant - StockTitan

Mar 21, 2025
pulisher
Mar 20, 2025

Immuneering reports Q4 EPS (58c), consensus (44c) - TipRanks

Mar 20, 2025
pulisher
Mar 20, 2025

Immuneering Corp SEC 10-K Report - TradingView

Mar 20, 2025
pulisher
Mar 20, 2025

Immuneering Corporation Q4 Net Income USD 18.1 Million -March 20, 2025 at 04:54 pm EDT - Marketscreener.com

Mar 20, 2025
pulisher
Mar 20, 2025

Immuneering Breakthrough: New Cancer Drug Doubles Standard Treatment Success Rate - StockTitan

Mar 20, 2025
pulisher
Mar 20, 2025

Immuneering appoints Igor Matushansky as CMO - The Pharma Letter

Mar 20, 2025
pulisher
Mar 20, 2025

Immuneering appoints new Chief Medical Officer - Investing.com

Mar 20, 2025
pulisher
Mar 20, 2025

Former Ipsen Executive Who Led FDA-Approved Cancer Drug Joins Immuneering as CMO - Stock Titan

Mar 20, 2025

Immuneering Corp (IMRX) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Immuneering Corp 주식 (IMRX) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Schall Thomas J.
Director
Jun 17 '25
Buy
2.21
40,485
89,278
43,385
$20.42
price down icon 1.37%
$35.45
price up icon 0.65%
$21.06
price down icon 1.92%
$101.83
price down icon 0.41%
$105.86
price down icon 0.39%
biotechnology ONC
$244.00
price down icon 3.69%
자본화:     |  볼륨(24시간):